Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: June 6, 2011
Last updated: May 2, 2015
Last verified: May 2015
This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or metastatic endometrial cancer.

Condition Intervention Phase
Solid Tumors and Advanced Endometrial Cancer
Endometrial Cancer
Second-line Treatment
Drug: TKI258
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Progression Free Survival (PFS) Rate [ Time Frame: up to 18 weeks ] [ Designated as safety issue: No ]
    The 18-week PFS was defined as the percentage of participants who did not have a progression event at week 18. Participants who progressed, died, had response assessment of unknown (UNK) or discontinued before 18 weeks of observation without progression were counted as "failure". Progressive disease was assessed as per investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Secondary Outcome Measures:
  • Overall Response Rate (ORR) [ Time Frame: Baseline and every 6 weeks until disease progression, up to 18 weeks ] [ Designated as safety issue: No ]
    ORR is defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR).

  • Disease Control Rate (DCR) [ Time Frame: Baseline and every 6 weeks until disease progression, up to 18 weeks ] [ Designated as safety issue: No ]
    DCR was defined as the percentage of participants with a best overall response of CR or PR or stable disease (SD).

  • Duration of Response (DR) [ Time Frame: up to 18 weeks ] [ Designated as safety issue: No ]
    Duration of response was defined for participants with a CR or PR as the time from the date of the first documented response (CR or PR) to the date of the first documented progression or death due to disease. If a participants did not have a progression event, duration of response was censored at the date of the last adequate tumor assessment before the data analysis cut-off date or the antineoplastic therapy start date or the death date.

  • Overall Survival (OS) [ Time Frame: up to 18 weeks ] [ Designated as safety issue: No ]
    OS was defined as the time from date of treatment to the date of death from any cause. If a participant was not known to have died at the date of analysis cut-off, the OS was censored at the last date of contact.

  • Progression Free Survival (PFS) [ Time Frame: up to 18 weeks ] [ Designated as safety issue: No ]
    PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. If a participant did not have an event, PFS was censored at the date of last adequate response assessment before the data analysis cut-off date or the start date of new antineoplastic therapy after study drug discontinuation.

  • Number of Participants With Adverse Events, Serious Adverse Events and Deaths [ Time Frame: up to 30 days after the last dose of study drug, up to 18 weeks ] [ Designated as safety issue: Yes ]
    Adverse event monitoring was conducted throughout the study.

Enrollment: 53
Study Start Date: November 2011
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TKI258
1 treatment arm (single agent TKI258), with patients classified into 2 groups based on their FGFR2 mutation status
Drug: TKI258
Other Name: dovitinib


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histologically confirmed diagnosis of advanced and/or metastatic endometrial cancer with available tissue specimen (either archival tissue or fixed fresh biopsy)
  • Female patients ≥ 18 years old
  • Documented radiologically confirmed progression of disease after prior first-line treatment evidence of progressive disease
  • ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
  • At least one measurable lesion as per RECIST

Exclusion Criteria:

  • Previous treatment with an FGFR inhibitor
  • More than one line of treatment for advanced or metastatic disease
  • Patients with uterine sarcomas, adenosarcoma, and malignant Mullerian tumors
  • Patients with isolated recurrences (vaginal, pelvic, or para-aortic) potentially curative with radiation therapy or surgery
  • Known central nervous system (CNS) metastases
  • Malignancy within 3 years of study enrollment Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01379534

  Hide Study Locations
United States, Alabama
University of South Alabama / Mitchell Cancer Institute Univ South Alabama
Mobile, Alabama, United States, 36688
United States, California
St. Jude Heritage Medical Group St Jude
Fullerton, California, United States, 92835
USC/Kenneth Norris Comprehensive Cancer Center USC 2
Los Angeles, California, United States, 90033
Cedars Sinai Medical Center TKI258A2211 (SC)
Los Angeles, California, United States, 90048
University of California at Los Angeles UCLA 3
Los Angeles, California, United States, 90095
United States, Colorado
Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer
Greenwood Village, Colorado, United States
United States, Florida
Florida Hospital Cancer Institute FL Hosp
Orlando, Florida, United States, 32804
United States, Indiana
Indiana University Health Goshen Center for Cancer IU Simon Cancer
Indianapolis, Indiana, United States, 46202
United States, Iowa
University of Iowa Hospitals & Clinics SC
Iowa City, Iowa, United States, 52242
United States, Massachusetts
Dana Farber Cancer Institute SC
Boston, Massachusetts, United States, 02115
United States, Nebraska
Southeast Nebraska Oncology Cancer Center
Lincoln, Nebraska, United States, 68510
United States, North Carolina
Hope A Woman's Cancer Center
Asheville, North Carolina, United States, 28806
Duke University Medical Center Duke3
Durham, North Carolina, United States, 27710
United States, Tennessee
Community Oncology Research Network
Chattanooga, Tennessee, United States, 37403
The West Clinic SC
Memphis, Tennessee, United States, 38120
United States, Texas
Texas Oncology, P.A. Austin
Bedford, Texas, United States, 76022
Texas Oncology, P.A. Tex Onc (3)
Bedford, Texas, United States, 76022
Texas Oncology, P.A. SC
Fort Worth, Texas, United States, 76104
South Texas Oncology and Hematology, PA South Tex Onc
San Antonio, Texas, United States, 78258
United States, Virginia
Virginia Oncology Associates VOA - Lake Wright
*see Various Departments*, Virginia, United States
United States, Washington
Cancer Care Northwest SC
Spokane, Washington, United States, 99202
Novartis Investigative Site
Belo Horizonte, MG, Brazil, 30150-270
Novartis Investigative Site
Porto Alegre, RS, Brazil, 90610-000
Novartis Investigative Site
Ribeirao Preto, SP, Brazil, 14048-900
Novartis Investigative Site
Genova, GE, Italy, 16132
Novartis Investigative Site
Monza, MB, Italy, 20900
Novartis Investigative Site
Milano, MI, Italy, 20133
Novartis Investigative Site
Milano, MI, Italy, 20141
Novartis Investigative Site
Pisa, PI, Italy, 56126
Novartis Investigative Site
Roma, RM, Italy, 00168
Novartis Investigative Site
Candiolo, TO, Italy, 10060
Korea, Republic of
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 135-710
Novartis Investigative Site
Seoul, Korea, Republic of, 738-736
New Zealand
Novartis Investigative Site
Grafton, Auckland, New Zealand
Novartis Investigative Site
Cordoba, Andalucia, Spain, 14004
Novartis Investigative Site
Málaga, Andalucia, Spain, 29010
Novartis Investigative Site
Oviedo, Asturias, Spain, 33006
Novartis Investigative Site
Sabadell, Barcelona, Spain, 08208
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Majadahonda, Madrid, Spain, 28222
Novartis Investigative Site
Murcia, Spain, 30008
United Kingdom
Novartis Investigative Site
Glasgow, United Kingdom, G12 0YN
Novartis Investigative Site
Leeds, United Kingdom, LS9 7TF
Novartis Investigative Site
London, United Kingdom, NW1 2BU
Novartis Investigative Site
Nottingham, United Kingdom, NG5 1PB
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01379534     History of Changes
Other Study ID Numbers: CTKI258A2211  2011-000266-35 
Study First Received: June 6, 2011
Results First Received: March 18, 2015
Last Updated: May 2, 2015
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Belgium: Federal Agency for Medicines and Health Products, FAMHP
Germany: Federal Institutes for Drugs and Medical Devices (BfArM)
Netherlands: Medicines Evaluation Board
Singapore: Health Science Authority
Italy: Italian Medicines Agency (AIFA)

Keywords provided by Novartis:
Solid tumors,
advanced endometrial cancer,
Endometrial Cancer,
Second-line treatment,
Endometrial Neoplasms,
Uterine Neoplasms,
Female Genital Neoplasms,
Uterine Diseases,
Female Genital Diseases,
Oral Administration,
CHIR 258,
TKI 258

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female processed this record on December 05, 2016